Ashling Wahner

Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.

Drs Park and Liu discuss the use of amivantamab plus lazertinib in EGFR-mutated non–small cell lung cancer.

Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.

Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.

Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.

Lunresertib and camonsertib combination showed promising efficacy in endometrial and platinum-resistant ovarian cancers, with ORRs of 25.9% and 37.5%, respectively.

Taletrectinib showed an 88.8% ORR in TKI-naive and 55.8% in previously treated ROS1-positive NSCLC patients.

Neratinib is now recommended for HER2-mutated recurrent/metastatic cervical cancer, with a Category 2A status in NCCN Guidelines.

Nivolumab and ipilimumab combination approved for MSI-H/dMMR metastatic colorectal cancer in the EU, a first for dual checkpoint inhibitors.

Dr Moreau discusses key findings from an analysis of minimal residual disease negativity dynamics from IMROZ and the potential future implications of these findings for patients with newly diagnosed multiple myeloma.